復發性外陰陰道念珠菌症（RVVC）：市場展望、流行病學、競爭格局、市場預測報告（2025-2035年）

市場概覽

• 預計到 2035 年，法國 RVVC 市場將從約 2,400 萬美元成長到 6,000 萬美元，這表明市場將大幅擴張。
• 市場成長受以下因素支撐：
• 擴大新型抗真菌療法在復發性疾病治療的應用
• 人們對抗藥性和復發性性行為感染的認知提高，診斷數量也隨之增加。
• 市場規模的擴大是由長期抑制治療策略和對永續治療方案日益成長的需求所驅動的。
• 未來市場成長將取決於下一代抗真菌藥物、對抗抗藥性的療法以及預防性治療方法，包括疫苗和免疫療法。

復發性外陰陰道念珠菌症（RVVC）概述

復發性外陰陰道念珠菌症（RVVC）是一種慢性婦科疾病，其特徵是外陰陰道感染疾病反覆發作，通常定義為每年出現三次或三次以上症狀性復發。雖然大多數病例是由白色念珠菌引起的，但非白色念珠菌，例如光滑念珠菌，也日益受到重視，這些念珠菌通常具有抗真菌藥物，治療難度較高。常見症狀包括外陰陰道搔癢、灼痛、刺激感、疼痛和異常分泌物，這些症狀會嚴重影響患者的生活品質、心理健康和日常活動。

復發性外陰陰道念珠菌病（RVVC）的發病機制涉及真菌致病性、宿主免疫反應、荷爾蒙因素、抗生素暴露以及陰道微生物群失衡等多種因素的複雜相互作用。雖然糖尿病、免疫抑制和荷爾蒙變化等某些危險因子會導致疾病復發，但許多患者的發病原因並不明確。診斷主要依賴臨床評估，並輔以真菌培養或分子檢測，以鑑定念珠菌種類並檢測抗藥性感染疾病。

標準治療方法包括局部或口服Azole抗真菌藥物藥物，特別是長期服用Fluconazole的抑制療法。然而，停藥後復發和抗真菌藥物抗藥性的日益增強仍然是重要的臨床挑戰。近期核准的新型抗真菌藥物和新型免疫調節療法的出現，正在拓展治療選擇，並滿足長期疾病管理中重要的未滿足需求。

主要亮點

• 據預測，到 2035 年，德國確診的 RVVC 病例數將從約 622,099 例增加到 715,204 例，反映出疾病負擔日益加重。
• 非白色念珠菌屬的日益普及導致了抗真菌藥物抗藥性的增加和治療的複雜性。
• 持續的復發和病情加重持續對患者的生活品質和獲得醫療保健服務產生重大影響。
• 新型抗真菌藥物正在為復發性或抗藥性真菌感染患者拓展治療選擇。
• 人們越來越重視女性健康，診斷檢測技術也不斷進步，這使得患者更容易被辨識出來，治療也更容易被接受。

格式化和更新訊息

• 詳細報告（PDF）
• 市場預測模型（基於微軟Excel）
• 流行病學數據（MS Excel，互動式工具）
• 高階主管洞察（PPT簡報）
• 其他功能：定期更新、自訂和顧問支援。
• 根據 Thelansis 的政策，我們確保所有最新更新在發布前都反映在報告內容和市場模型中。

主要問題

• 我們如何最佳化 G8 市場（美國、歐盟 5 國、日本、中國）的藥物開發與生命週期管理策略？
• 從發病率、盛行率、人群組成以及接受藥物治療的患者人數來看，患者數量分別是多少？
• 未來十年市場收入和病患佔有率的預測是多少？
• 哪些因素對市場趨勢影響最大？
• 受訪專家對目前和新興的治療方法有何看法？
• 哪款在研發線產品最有前景？其上市潛力及未來市場定位如何？
• 主要未被滿足的需求是什麼？ KOL 對目標受眾有何期望？
• 為確保藥物核准並順利進入市場，必須滿足哪些關鍵的監管和支付方要求？

目標國家

• G8
  • 美國
  • EU5
    • 法國
    • 德國
    • 義大利
    • 西班牙
    • 英國
  • 日本
  • 中國

大公司

• LimmaTech Biologics AG
• Mycovia Pharmaceuticals Inc.

目錄

第1章：主要調查結果及分析師說明

• 主要趨勢：市場概況、SWOT分析、商業性利益與風險等。

第2章：疾病背景

• 疾病定義、分類、病因和病理生理學、藥物標靶等。

第3章：流行病學

• 重點
• 發病率/盛行率
• 已確診並接受藥物治療的患者人數
• 合併症
• 其他相關患者群

第4章 市場規模及預測

• 重點
• 市場促進因素與限制因素
• 按藥物類別分類的趨勢
• 各國具體趨勢

第5章 競爭情勢

• 目前的治療方法
• 重點
• 診斷和治療過程/演算法
• 主要治療方法概述及KOL洞察
• 新興治療方法
• 重點
• 值得關注的後期新興治療方法—概述、市場上市預期以及KOL洞察。
• 值得關注的早期研發管線

第6章：未滿足的需求與TPP分析

• 主要未滿足的需求以及透過新興治療方法實現的未來可能性
• TPP分析與KOL展望

第7章 監理與報銷環境

第8章附錄

Recurrent Vulvovaginal Candidiasis (RVVC) Market Outlook

Thelansis's "Recurrent Vulvovaginal Candidiasis (RVVC) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Recurrent Vulvovaginal Candidiasis treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Recurrent Vulvovaginal Candidiasis (RVVC) Overview

Recurrent vulvovaginal candidiasis (RVVC) is a chronic gynecological condition characterized by recurrent episodes of vulvovaginal Candida infection, typically defined as three or more symptomatic episodes within a year. The majority of cases are caused by Candida albicans, although non-albicans species such as Candida glabrata are increasingly recognized and are often associated with antifungal resistance and treatment difficulty. Common symptoms include vulvovaginal itching, burning, irritation, pain, and abnormal discharge, significantly impacting quality of life, emotional well-being, and daily functioning.

RVVC pathogenesis involves complex interactions between fungal virulence, host immune response, hormonal factors, antibiotic exposure, and vaginal microbiome imbalance. While certain risk factors such as diabetes, immunosuppression, and hormonal changes contribute to disease recurrence, many patients present without identifiable underlying causes. Diagnosis relies on clinical evaluation supported by fungal culture or molecular testing to confirm Candida species and detect resistant infections.

Standard management includes topical or oral azole antifungal therapy, particularly long-term fluconazole suppression; however, recurrence following treatment discontinuation and increasing antifungal resistance remain major clinical challenges. Recently approved novel antifungal therapies and emerging immunomodulatory approaches are expanding the treatment landscape and addressing significant unmet needs in long-term disease control.

Key Highlights

• In Germany, the diagnosed RVVC prevalence pool is projected to increase from approximately 622,099 to 715,204 by 2035, reflecting a growing disease burden.
• Increasing prevalence of non-albicans Candida species is contributing to greater antifungal resistance and treatment complexity.
• Persistent recurrence and relapse continue to significantly impact patient quality of life and healthcare utilization.
• Novel antifungal agents are expanding treatment options for patients with recurrent or resistant disease.
• Growing awareness of women's health conditions and improved diagnostic testing are supporting increased patient identification and treatment uptake.

Market Overview

• The France RVVC market is projected to grow from approximately $24 MN to $60 MN by 2035, reflecting notable market expansion.
• Market growth is supported by:
• Increasing adoption of novel antifungal therapies for recurrent disease management
• Rising awareness and diagnosis of resistant and recurrent infections
• Market value growth is driven by long-term suppressive treatment strategies and increasing demand for durable therapeutic options.
• Future market growth will depend on next-generation antifungal agents, resistance-targeted therapies, and preventive therapeutic approaches including vaccines and immunotherapies.

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support
• As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025-2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market's trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

• LimmaTech Biologics AG
• Mycovia Pharmaceuticals Inc.

Table of Contents

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risks, etc.

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets, etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
• Key takeaways
• Dx and Tx journey/algorithm
• Key current therapies - profiles and KOL insights
• Emerging therapies
• Key takeaways
• Notable late-phase emerging therapies - profiles, launch expectations, KOL insights
• Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)